Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Debt Ratio (2020 - 2023)

Historic Debt Ratio for C4 Therapeutics (CCCC) over the last 4 years, with Q2 2023 value amounting to 0.03.

  • C4 Therapeutics' Debt Ratio rose 2203.13% to 0.03 in Q2 2023 from the same period last year, while for Jun 2023 it was 0.03, marking a year-over-year increase of 2203.13%. This contributed to the annual value of 0.03 for FY2022, which is 2542.18% up from last year.
  • According to the latest figures from Q2 2023, C4 Therapeutics' Debt Ratio is 0.03, which was up 2203.13% from 0.03 recorded in Q1 2023.
  • C4 Therapeutics' Debt Ratio's 5-year high stood at 0.04 during Q3 2020, with a 5-year trough of 0.02 in Q2 2021.
  • In the last 4 years, C4 Therapeutics' Debt Ratio had a median value of 0.02 in 2020 and averaged 0.03.
  • As far as peak fluctuations go, C4 Therapeutics' Debt Ratio crashed by 5164.1% in 2021, and later surged by 2973.3% in 2023.
  • Quarter analysis of 4 years shows C4 Therapeutics' Debt Ratio stood at 0.03 in 2020, then dropped by 15.42% to 0.02 in 2021, then rose by 25.42% to 0.03 in 2022, then increased by 3.41% to 0.03 in 2023.
  • Its Debt Ratio stands at 0.03 for Q2 2023, versus 0.03 for Q1 2023 and 0.03 for Q4 2022.